PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

Size: px
Start display at page:

Download "PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update"

Transcription

1 PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease in deal value was the result of a reduced number of mega and other large deals (especially deals greater than $1 billion). Overall, only Asia Pacific had a moderate increase in deal activity, while there was a decline from other regions. The reduction in deal activity relative to the prior year continues to be driven by a combination of general market forces, including uncertainty around potential interest rate movements and industry specific factors. Recent media attention around drug pricing has driven lower deal volume in the specialty pharma space as potential acquirers wait to see how this trend develops in the next few quarters. As industry participants continue to re-evaluate their portfolios of assets, deal volumes may trend upwards toward more historical levels for the industry by the end of the year. However, there may continue to be lower total deal value relative to historical levels as potential acquirers become more disciplined with deal pricing and look for smaller targets. Value by thenumbers $42B Volume by the numbers 90 50% deal value versus Q2 16 5% deal volume versus Q2 16 Source: Thomson Reuters, Capital IQ, PwC analysis 65% deal value versus Q % deal volume versus Q3 15 Despite the short-term trends in the market, the underlying rationale for completing deals in the PLS sector continues to remain the same, as success in the broader industry is driven by access to scarce assets. Dimitri Drone, Global Pharma & Life Sciences Deals Leader Q3 16 highlights A total of 90 deals were announced amounting to $42 billion in disclosed deal value during Q3 16. Of these, 26 transactions were completed, while 64 are pending. There were 7 transactions worth $1 billion or more during Q3 16. The transaction with the highest value was worth $14.1 billion. In terms of deal value, biotechnology was the largest segment with deals worth $.9 billion. The pharmaceuticals segment followed with 37 deals worth $8.5 billion. Overall, 81% or $33.8 billion of the total PLS deal value involved companies in the United States. Asia-Pacific was the only geography to grow on a Q-o-Q basis in both volume and value, with respective increases of 11% and 23%, helping to partially offset the drop in overall activity for the quarter. Q3 16 update 1

2 Deal value ($ in billions) Number of deals Highlights of Q3 16 deal activity M&A market drops While the number of deals announced in Q3 16 was down significantly relative to 15 levels, volumes in the last three quarters of 16 have been relatively stable. After a relatively strong 15, four out of the last six quarters experienced deal values below $50 billion. These trends suggest that deal volumes in the future have the ability to trend upwards; however, it is likely that deal values may continue to be depressed until uncertainty around general economic factors and industry conditions are mitigated. Pharma & life sciences deal volume and value $121.8 $86.0 $47.6 $118.7 $34.2 $36.7 $82.5 $ Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Announced deal value Announced deal volume Market multiples Median Q3 16 enterprise value/revenue multiples decreased compared to Q2 16 and continue to be down relative to 15 levels. Meanwhile, average enterprise value/revenue trading multiples for the largest participants in the biotechnology and pharmaceutical sub-sectors have stayed relatively flat Q-o-Q since Q4 14, while medical device/equipment multiples have been slowly trending upward. EV/revenue transaction multiples 25.0x.0x 15.0x 10.0x 5.0x 0.0x Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 3rd Quartile 1st Quartile Median Venture capital financing Venture capitalists invested $10.6 billion in 891 deals in the third quarter of 16, according to the MoneyTree Report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. The biotechnology industry received the second largest amount of venture capital behind software, with $1.8 billion going into 87 deals, representing a 5% increase in dollars invested and a 16% decrease in the number of deals, compared with the second quarter of 16. Within the biotechnology sector the largest investment was raised by Modernatix Inc., an early/clinical stage company, in the amount of million. Investments in the sector declined 15% in dollars invested and 30% in number of deals compared with the third quarter of 15. Investments in the life sciences sector (biotechnology and medical devices combined) during the third quarter accounted for $2.5 billion going into 156 deals, increasing 8% in dollars invested and declining 7% in number of deals compared with the second quarter of 16. Investments in life sciences companies accounted for 24% of all venture capital deployed to the startup ecosystem in the third quarter, up 9% from a share of 15% in the previous quarter. Investments in life sciences as a whole declined 17% in dollars invested and 26% in number of deals compared with the third quarter of 15. Q3 16 update 2

3 Key trends and insights Announced deal values by target region for Q3 16 United States $31.5 billion; 75.8% Western Europe $3.2 billion; 7.6% Asia-Pacific $5.7 billion; 13.7% Rest of the World $1.2 billion; 2.9% Deals by target geography While Asia Pacific had a modest deal volume growth of 23% in Q3 16 compared to Q2 16, United States, Western Europe, and other geographies decreased by 5%, 40% and 33%, respectively in the same period. United States (excluding Outbound) continued to lead the global PLS deal value (76% share or $31.5 billion) but experienced a decline in volume and value this quarter on both a Q-o-Q and Y-o-Y basis. Strategic acquirers continued to lead in deal activity over financial buyers in Q3 16 with an aggregate of $39.8 billion in deal value (96% share in total deal value) and 77 deals (86% of total deal volume). US and foreign deals The major local and foreign activity occurring during Q3 16 include: Inbound Galenica AG, of Switzerland, acquired the entire share capital of Relypsa Inc., a Redwood City based clinical stage biopharmaceutical company, for $1.5 billion. Outbound Pfizer Inc. agreed to acquire the small molecule antibiotics business of AstraZeneca PLC, a UK based manufacturer and wholesaler of pharmaceuticals, for $1.6 billion. Local Pfizer Inc. merged with Medivation Inc., a San Francisco based manufacturer of pharmaceutical preparation, for $ 14.1 billion, via tender offer. Foreign Shanghai Fosun Pharmaceutical (Group) Co. Ltd. of China agreed to acquire 86% interest in Gland Pharma Ltd., an India-based manufacturer of pharmaceutical preparation, for $1.3 billion. Q3 16 update 3

4 Highlights of Q3 16 deal activity Key announced transactions The number of deals that surpassed the billion-dollar mark halved during the quarter from 14 deals in Q2 16 to 7 deals in Q3 16. The top 5 deals for the quarter were: Merger of Pfizer Inc. with Medivation Inc., a cancer dug company, for $14.1 billion, via tender offer. Johnson & Johnson agreed to a $4.3 billion deal to acquire Abbott Medical Optics Inc., a manufacturer and wholesaler of eye care surgical equipment and products, from Abbott Laboratories. Danaher Corp. agreed to acquire Cepheid Inc., a manufacturer and marketer of micro fluidic systems for $3.9 billion. Pfizer Inc. agreed to acquire the small molecule antibiotics business of AstraZeneca PLC, for $1.6 billion. Allergan PLC agreed to acquire the entire share capital of Tobira Therapeutics Inc., a manufacturer of pharmaceutical preparation, for an estimated total value of $1.5 billion, via tender offer. Deal volume by transaction size Transactions with value between $500 million and $1 billion increased more than 300% in both deal volume and value on a Q-o-Q basis. Deals valued more than $1 billion experienced a volume and value decline of 50% and 61%, respectively. Deals between $50 million and $100 million increased 43% in value and 25% in volume on a Q-o-Q basis. Announced deal volume and value by sub-sector Biotechnology was the most active segment in terms of value accounting for 51% of the total deal value in Q3 16. Pharmaceutical had the highest volume of deals 37 deals representing 41% of the total deals of the quarter. The segment had the second highest deal value of $8.4 billion. Medical devices witnessed a decline of 56% in its deal value - from $16.7 billion in Q3 15 to $7.4 billion in Q3 16. Deal value in the diagnostics segment increased by more than 250% on a Y-o-Y basis although its deal volume declined by 60% during the same period. # of deals $15-$50m 38% Biotechnology $,982 $50-$100m 22% 37 Pharmaceuticals $8,457 $100-$250m $250-$500m $500m-$1b $1b+ 12% 10% 10% 8% Medical Devices $7,423 Diagnostics $4,011 Services $671 Note: Deals included in this chart are those that have disclosed value. Q3 16 update 4

5 About PwC s Deals Practice Authors Dimitri Drone Partner, Global Pharmaceutical and Life Sciences Leader PwC s Deals Practice (973) James Woods Principal, PwC s Deals Practice (617) Brian Geiger Director, PwC s Deals Practice (312) For a deeper discussion on pharmaceutical and life sciences deal considerations, please contact our practice leader: Bob Saada US Deals Leader, PwC s Deals Practice (646) PwC s Deals professionals help clients understand the risks in transactions so they can be confident that they are making informed strategic decisions. From deal negotiations to capturing synergies during integration, we help clients gain value and ultimately deliver this value to stakeholders. For companies in distressed situations, we advise on crisis avoidance, financial and operational restructuring, and bankruptcy. PwC s Deals Practice can advise pharmaceutical and life sciences companies and PLS-focused private equity firms on a range of M&A decisions, from identifying acquisition or divestiture candidates and performing detailed buy-side diligence, through developing strategies for capturing post-deal profits, to exiting a deal through a sale, carve-out, or IPO. Our seasoned deals teams combine deep pharmaceutical and life sciences industry skills with local market knowledge. With more than 15,000 deals professionals in over 1 countries, we can deploy a deals team virtually anywhere your company operates or executes transactions. Although each deal is unique, most will benefit from the broad experience we bring to delivering strategic M&A advice, due diligence, transaction structuring, M&A tax, merger integration, valuation, and post-deal services. In short, we offer integrated solutions tailored to your particular deal situation and designed to help you complete and extract peak value within your risk profile, whether your focus is deploying capital through an acquisition or joint venture, raising capital through an IPO or private placement, or harvesting an investment through the divestiture process. For more information about M&A and related services in the pharmaceutical and life sciences industry, please visit or For our views on the health industries sector, refer to the US Health Services reports on the deals section of our website. About the data We define M&A activity as mergers and acquisitions in which targets are US based companies acquired by US or foreign buyers, or foreign targets acquired by US or foreign pharmaceutical and life sciences companies. We define divestitures as the sale of a portion of a company (not a whole entity) by a US-based or foreign seller. We have based our findings on data provided by industry-recognized sources. Specifically, values and volumes used throughout this report are based on announcement-date for transactions with a disclosed deal value greater than $15 million, as provided by Thomson Reuters as of June 30, 16, and supplemented by additional independent research. Information related to previous periods is updated periodically based on new data collected by Thomson Reuters for deals closed during previous periods but not reflected in previous data sets. Deal information was sourced from Thomson Reuters and includes deals for which buyers or targets fall into one of the PLS industry sectors: biotechnology, medical devices, medical diagnostics, pharmaceuticals, or services (i.e., contract research organizations). Certain adjustments have been made to the information to exclude transactions that are not specific to the PLS industry. Capital market and equity return information is sourced from Capital IQ. 16 PwC. All rights reserved. PwC and PwC US refer to PricewaterhouseCoopers LLP, a Delaware limited liability partnership, which is a member firm of PricewaterhouseCoopers International Limited, each member firm of which is a separate legal entity. This document is for general information purposes only, and should not be used as a substitute for consultation with professional advisors vc

PwC Deals $119.1B. Executive summary. Global Pharma & Life Sciences Deals Insights Q2 2018

PwC Deals $119.1B. Executive summary. Global Pharma & Life Sciences Deals Insights Q2 2018 PwC Deals Global Pharma & Life Sciences Deals Insights Q 18 The increase in deal activity in Q 18 sets the stage for a strong second half of the year. Companies continue to review their portfolios for

More information

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year

Medtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for

More information

2013 venture capital trends summary

2013 venture capital trends summary 213 venture capital trends summary Prepared by: Hitesh Kothari, Director, McGladrey LLP hitesh.kothari@mcgladrey.com August 213 Fundraising by venture capital funds In the first half of 213, 88 venture

More information

Silicon Valley Venture Capital Survey Second Quarter 2018

Silicon Valley Venture Capital Survey Second Quarter 2018 fenwick & west Silicon Valley Venture Capital Survey Second Quarter 2018 Full Analysis Silicon Valley Venture Capital Survey Second Quarter 2018 fenwick & west Full Analysis Cynthia Clarfield Hess, Mark

More information

VENTURE CAPITAL INVESTING REACHES HIGHEST LEVEL SINCE Q WITH $13.0 BILLION INVESTED DURING Q2 2014, ACCORDING TO THE MONEYTREE REPORT

VENTURE CAPITAL INVESTING REACHES HIGHEST LEVEL SINCE Q WITH $13.0 BILLION INVESTED DURING Q2 2014, ACCORDING TO THE MONEYTREE REPORT Contacts: Clare Chachere, PwC US, 512-867-8737, clare.chachere@us.pwc.com Jeffrey Davidson, Brainerd Communicators for PwC, 212-739-6733, davidson@braincomm.com Ben Veghte, NVCA, 703-778-9292, bveghte@nvca.org

More information

Silicon Valley Venture Capital Survey Third Quarter 2017

Silicon Valley Venture Capital Survey Third Quarter 2017 fenwick & west Silicon Valley Venture Capital Survey Third Quarter 2017 Full Analysis Silicon Valley Venture Capital Survey Third Quarter 2017 fenwick & west Full Analysis Cynthia Clarfield Hess, Mark

More information

Moving Ahead. Third-quarter Technology venture capital investment increased 33 percent yearover-year. percent quarter-over-quarter.

Moving Ahead. Third-quarter Technology venture capital investment increased 33 percent yearover-year. percent quarter-over-quarter. Moving Ahead Third-quarter Technology venture capital investment increased 33 percent yearover-year but decreased 6 percent quarter-over-quarter October 2 PwC US venture capital funding for the Technology

More information

VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000

VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN DOUBLES IN Q WITH STRONGEST QUARTER FOR BIOTECH OFFERINGS SINCE 2000 CONTACTS Laura Cruz Tenor Communications for NVCA 1.917.406.7517 laura@tenorcom.com Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY MORE THAN

More information

Private Equity Market Update. February 2013

Private Equity Market Update. February 2013 Private Equity Market Update February 213 U.S. Private Equity Deal Activity Deal activity in the first three quarters of 212 was lower than the corresponding quarters in 211 due to a number of factors.

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 3Q 2015 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp

1h Fenwick. Trends in Terms of U.S. Life Science Venture Financings. First Half fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Fenwick fenwick & west llp 1h 2012 Trends in Terms of U.S. Life Science Venture Financings First Half 2012 Survey Introduction

More information

Trends in Terms of U.S. Life Science Venture Financings. Full Year Fenwick. fenwick & west llp

Trends in Terms of U.S. Life Science Venture Financings. Full Year Fenwick. fenwick & west llp 2012 Trends in Terms of U.S. Life Science Venture Financings Full Year 2012 Fenwick fenwick & west llp 2012 Trends in Terms of U.S. Life Science Venture Financings Full Year 2012 Survey Intro and Background

More information

January Bob DeSutter Managing Director Co-Head of Health Care

January Bob DeSutter Managing Director Co-Head of Health Care January 2007 Dear Friends and Clients, For much of our 112 year history, serving innovative health care companies has been an important part of our mission at Piper Jaffray. Our goal is to be lead advisor

More information

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd.

IVC-MEITAR HIGH-TECH EXITS H1/ 2015 REPORT. IVC-Meitar 2014 Exits Report Prepared by IVC Research Center Ltd. IVC-MEITAR HIGH-TECH EXITS H1/ 215 REPORT IVC-Meitar 214 Exits Report Prepared by IVC Research Center Ltd. Israeli High-Tech Exit Highlights Exit proceeds in H1/215 reached ¾ of total exits for 214 Average

More information

Israel Venture Capital Investments Report Q3 2017

Israel Venture Capital Investments Report Q3 2017 Israel Venture Capital Investments Report Q3 2017 NOVEMBER 2017 Summary of Israeli Venture Capital Raising Q3/2017 +14% from Q2/2017 Israeli high-tech capital raising summed up to $1.44B @ ALL RIGHTS RESERVED.

More information

Venture-Backed Exit Activity Shows Improved Signs of Life in Q1 2010

Venture-Backed Exit Activity Shows Improved Signs of Life in Q1 2010 CONTACTS Channa Brooks Tenor Communications for NVCA 1.302.368.2345 channa@tenorcom.com Daniel Billings Thomson Reuters 1.646 223 5985 daniel.billings@thomsonreuters.com Exit Activity Shows Improved Signs

More information

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010)

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010) Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2010) Background We analyzed the terms of venture financings for 126 companies headquartered in Silicon Valley that reported raising

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 1Q 2018 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

The percentage of Series A rounds declined significantly, to 12% of all deals.

The percentage of Series A rounds declined significantly, to 12% of all deals. Silicon Valley Venture Capital Survey Fourth Quarter 2012 Barry Kramer and Michael Patrick Fenwick fenwick & west llp Background We analyzed the terms of venture financings for 116 companies headquartered

More information

Mara H. Rogers, Partner Norton Rose Fulbright

Mara H. Rogers, Partner Norton Rose Fulbright Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers

More information

VentureSource Europe -- 3Q 2014

VentureSource Europe -- 3Q 2014 Europe -- 3Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, and liquidity. The included charts and graphs offer a

More information

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

2Q13. Trends in Terms of Venture Financings in Silicon Valley. Second Quarter fenwick & west llp

2Q13. Trends in Terms of Venture Financings in Silicon Valley. Second Quarter fenwick & west llp 2Q13 Trends in Terms of Venture Financings in Silicon Valley Second Quarter 2013 Fenwi wick fenwick & west llp Silicon Valley Venture Capital Survey Second Quarter 2013 Barry Kramer and Michael Patrick

More information

CANADIAN PRIVATE EQUITY BUYOUT REVIEW

CANADIAN PRIVATE EQUITY BUYOUT REVIEW CANADIAN PRIVATE EQUITY BUYOUT REVIEW First Half 2016 REUTERS Table of Contents Canada s PE Buyout Market in Q2 2016 3 $ Invested and # Companies Financed 5 Top Buyout Deals 9 Canada by Market Segment

More information

Average M&A Deal Size at Highest Level Since 2004

Average M&A Deal Size at Highest Level Since 2004 CONTACTS Ben Veghte NVCA 1.703.778.9292 bveghte@nvca.org Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY MAINTAINS MOMENTUM WITH BEST QUARTER

More information

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

M&A Update 1H Proven. Focused. Trusted. Accounts Receivable Management Healthcare IT Revenue Cycle Management

M&A Update 1H Proven. Focused. Trusted. Accounts Receivable Management Healthcare IT Revenue Cycle Management M&A Update 1H 2017 Accounts Receivable Management Healthcare IT Revenue Cycle Management Proven. Focused. Trusted. 301-576-4000 www.greenberg-advisors.com Proven. Focused. Trusted Revenue Cycle Management

More information

2014 Global venture capital confidence survey results

2014 Global venture capital confidence survey results 2014 Global venture capital confidence survey results How confident are investors? August 13, 2014 Contents Survey methodology, demographics and key findings Economic trends Regional and country investing

More information

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Private Equity to us does not solely consist of preparing tailor-made acquisition, financing and exit structures, as well as developing and negotiatin

Private Equity to us does not solely consist of preparing tailor-made acquisition, financing and exit structures, as well as developing and negotiatin Private Equity to us does not solely consist of preparing tailor-made acquisition, financing and exit structures, as well as developing and negotiating, e.g., joint venture, purchase and participation

More information

Florida Venture Factbook

Florida Venture Factbook S E AT T L E SAN FRANCISCO NEW YORK LONDON Florida Venture Factbook 2019 pitchbook.com US + 1 206.623.1986 UK + 44 (0)207.190.9809 demo@pitchbook.com PG 1 Dear Attendee, On behalf of the Florida Venture

More information

Venture Capital Report

Venture Capital Report China 4Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for Chinese venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs offer

More information

VENTURE-BACKED IPO EXIT ACTIVITY KEEPS MOMENTUM WITH BEST FULL YEAR FOR NEW LISTINGS SINCE 2007; THIRD CONSECUTIVE QUARTER FOR 20+ OFFERINGS SINCE

VENTURE-BACKED IPO EXIT ACTIVITY KEEPS MOMENTUM WITH BEST FULL YEAR FOR NEW LISTINGS SINCE 2007; THIRD CONSECUTIVE QUARTER FOR 20+ OFFERINGS SINCE CONTACTS Laura Cruz Tenor Communications for NVCA 1.917.406.7517 laura@tenorcom.com Lauren Herman Thomson Reuters 1.646.223.5985 lauren.herman@thomsonreuters.com VENTURE-BACKED IPO EXIT ACTIVITY KEEPS

More information

Asia Pacific UK Cross border transactions. Corporate Finance PRECISE. PROVEN. PERFORMANCE.

Asia Pacific UK Cross border transactions. Corporate Finance PRECISE. PROVEN. PERFORMANCE. Asia Pacific UK Cross border transactions PRECISE. PROVEN. PERFORMANCE. Cross border transactions Our services Moore Stephens global network of offices allows us to combine expert knowledge and advice

More information

GLOBAL PRIVATE EQUITY Report Charts

GLOBAL PRIVATE EQUITY Report Charts GLOBAL PRIVATE EQUITY 2003 Report Charts THE WORLD VIEW Investment & Fund Raising Trends THE WORLD VIEW 2002 Main Headlines At least $102 billion of private equity and venture capital was invested globally

More information

Software was the Most Active and Highest Value Segment in 2015 with 1,288 Transactions Totaling $61.5 Billion in Reported Deal Value.

Software was the Most Active and Highest Value Segment in 2015 with 1,288 Transactions Totaling $61.5 Billion in Reported Deal Value. 2015 Summary of M&A and Investment Activity in the : 1,903 Totaling a $99.6 Billion Software was the Most Active and Highest Value Segment in 2015 with 1,288 Totaling $61.5 Billion in Deal Value December

More information

2013 Global venture capital confidence survey results. How confident are investors?

2013 Global venture capital confidence survey results. How confident are investors? 2013 Global venture capital confidence survey results How confident are investors? August 14, 2013 Contents Survey methodology, demographics and key findings Economic trends Regional and country investing

More information

Fortis to acquire strategic stake in Parkway Holdings, Singapore

Fortis to acquire strategic stake in Parkway Holdings, Singapore PRESS RELEASE Fortis to acquire strategic stake in Parkway Holdings, Singapore Landmark cross border deal in Healthcare sector out of India Move will establish Fortis as Asia s largest hospital network

More information

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context

More information

Software was the Most Active and Highest Value Segment in 3Q17 with 606 Transactions Totaling $29.4 Billion in Reported Deal Value

Software was the Most Active and Highest Value Segment in 3Q17 with 606 Transactions Totaling $29.4 Billion in Reported Deal Value jd1 3Q17 Summary of M&A and Investment Activity in the : 814 Totaling a $49.4 Billion Software was the Most Active and Highest Value Segment in 3Q17 with 606 Totaling $29.4 Billion in Deal Value During

More information

VentureSource U.S. -- 4Q 2013

VentureSource U.S. -- 4Q 2013 U.S. -- 4Q 2013 The following report presents DJX VentureSource s quarterly findings for U.S. venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs offer a comprehensive

More information

HOLDING REDLICH UPDATE - M & A

HOLDING REDLICH UPDATE - M & A 2018 M&A Review With many market commentators anticipating 2018 as a strong year for M&A, Holding Redlich s experience in the first half of 2018 has been consistent with this. The deals in which our team

More information

The Future of Growth and the Energy Industry

The Future of Growth and the Energy Industry The Future of Growth and the Energy Industry July 20, 2017 Grant Thornton LLP. All rights reserved. 1 Our Speakers Steve Toon Editor in Chief Oil and Gas Investor Kevin Schroeder National Managing Partner,

More information

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,

More information

Silicon Valley Venture Capital Survey Third Quarter 2017

Silicon Valley Venture Capital Survey Third Quarter 2017 fenwick & west Silicon Valley Venture Capital Survey Third Quarter 2017 First Look Silicon Valley Venture Capital Survey Third Quarter 2017 fenwick & west First Look Cynthia Clarfield Hess, Mark Leahy

More information

Venture financings in 3Q12 continued to show solid price increases from their prior round, but 3Q12 was not as strong as 2Q12.

Venture financings in 3Q12 continued to show solid price increases from their prior round, but 3Q12 was not as strong as 2Q12. Silicon Valley Venture Capital Survey Third Quarter 2012 Barry Kramer and Michael Patrick Fenwick fenwick & west llp Background We analyzed the terms of venture financings for 117 companies headquartered

More information

3Q13. Trends in Terms of Venture Financings in Silicon Valley. Third Quarter Fenwick. fenwick & west llp

3Q13. Trends in Terms of Venture Financings in Silicon Valley. Third Quarter Fenwick. fenwick & west llp 3Q13 Trends in Terms of Venture Financings in Silicon Valley Third Quarter 2013 Fenwick fenwick & west llp Silicon Valley Venture Capital Survey Third Quarter 2013 Barry Kramer and Michael Patrick Fenwick

More information

Venture Capital Industry Overview. Powered By:

Venture Capital Industry Overview. Powered By: Venture Capital Industry Overview Powered By: U.S. U.S. Fundraising Fundraising Slows in 1Q 05 Commitments to Venture Capital Funds $80 $83.5 Funds Raised ($B) $60 $40 $20 $0 $58.8 $50.5 $26.9 $17.1 $17.7

More information

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector

More information

Recent marquee transactions

Recent marquee transactions Recent marquee transactions EY the leading advisor in the Indian M&A market April 2014 EY refers to the global organization, and/or one or more of the independent member firms of Ernst & Young Global Limited

More information

Mergers and Acquisitions/ Private Equity. Providing In-Depth Deal Coverage for Buyers, Sellers, and Investors. Attorney Advertising

Mergers and Acquisitions/ Private Equity. Providing In-Depth Deal Coverage for Buyers, Sellers, and Investors. Attorney Advertising Mergers and Acquisitions/ Private Equity Providing In-Depth Deal Coverage for Buyers, Sellers, and Investors Attorney Advertising In every transaction, business perspective informs our legal strategy.

More information

AFTER NEARLY 3 YEARS OF STEADY GROWTH, U.S. VENTURE INVESTMENT PULLS BACK 7% IN 1 ST QUARTER TO $6.84 BILLION

AFTER NEARLY 3 YEARS OF STEADY GROWTH, U.S. VENTURE INVESTMENT PULLS BACK 7% IN 1 ST QUARTER TO $6.84 BILLION FOR IMMEDIATE RELEASE For more information: Adam Wade Dow Jones Financial Information Services (415) 439-6666 adam.wade@dowjones.com AFTER NEARLY 3 YEARS OF STEADY GROWTH, U.S. VENTURE INVESTMENT PULLS

More information

T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T AND PRIVATE EQUITY ENERGIZE GROWTH

T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T AND PRIVATE EQUITY ENERGIZE GROWTH 12 INVESMEN FUNDS VENURE CAPIAL AND PRIVAE EQUIY ENERGIZE GROWH Kalinka Iaquinto, Rio de Janeiro It all began in 2003, when Gustavo Caetano, a student of marketing, realized that the market for mobile

More information

Venture Capital Report

Venture Capital Report Venture Capital Report China 1 Q 2018 The following report presents Dow Jones VentureSource s quarterly findings for Chinese venture capital fundraising, investment, valuation, and liquidity. The included

More information

Venture Capital Report

Venture Capital Report Europe 4Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs

More information

2017 Venture Capital Update. Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017

2017 Venture Capital Update. Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017 2017 Venture Capital Update Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017 Agenda U.S. VC trends through year-end 2016 VC trends in Texas & Dallas Policy priorities

More information

TECH START-UP CONNECTING ACROSS GEOGRAPHIES

TECH START-UP CONNECTING ACROSS GEOGRAPHIES #ML15MayRathon TECH START-UP CONNECTING ACROSS GEOGRAPHIES Andrew Ray, Partner, Washington DC William Perkins, Partner, Boston James Chapman, Partner, Silicon Valley Joseph Statter, Managing Director,

More information

HOTELS, TOURISM & LEISURE. Hotels, Tourism & Leisure

HOTELS, TOURISM & LEISURE. Hotels, Tourism & Leisure HOTELS, TOURISM & LEISURE nem is one of Australasia s largest boutique business consultancy firms, which is able to draw on the significant skills and experience of over 50 partners across Australia and

More information

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

VentureSource China -- 3Q 2014

VentureSource China -- 3Q 2014 China -- 3Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for Chinese venture capital fundraising, investment, and liquidity. The included charts and graphs offer a comprehensive

More information

Life Sciences Tools, Diagnostics, & Services Q Industry Overview

Life Sciences Tools, Diagnostics, & Services Q Industry Overview Life Sciences Tools, Diagnostics, & Services Q4 2017 Industry Overview Life Sciences Tools, Diagnostics, & Services: Industry Overview Key Takeaways M&A activity has remained steady at high volumes of

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 3Q 2018 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA Press release Baar, 28 January 2008 Attractive portfolio of investments in biotech and medical technology to be opened to the public HBM BioVentures announces further information of its planned IPO on

More information

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2011)

Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2011) Trends in Terms of Venture Financings In Silicon Valley (Second Quarter 2011) Background We analyzed the terms of venture financings for 117 companies headquartered in Silicon Valley that reported raising

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

VentureSource China -- 1Q 2014

VentureSource China -- 1Q 2014 China -- 1Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for Chinese venture capital fundraising, investment, and liquidity. The included charts and graphs offer a comprehensive

More information

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 8, 2018 4Q17 Reflections Fundamentals Are Strong (Dollars in millions, except per unit amounts and unless otherwise stated)

More information

Cannabis Practice Group

Cannabis Practice Group Cannabis Practice Group McMillan LLP Vancouver Calgary Toronto Ottawa Montréal Hong Kong Cannabis mcmillan.ca Practice Group 1 Medical cannabis is booming and McMillan is at the forefront of developments

More information

MoneyTree Report Q PricewaterhouseCoopers National Venture Capital Association. Data provide by Thomson Reuters.

MoneyTree Report Q PricewaterhouseCoopers National Venture Capital Association. Data provide by Thomson Reuters. www.pwcmoneytree.com PricewaterhouseCoopers National Venture Capital Association TM MoneyTree Report Data provide by Thomson Reuters The MoneyTree results are in! This special report provides summary results

More information

Venture Capital Report

Venture Capital Report Venture Capital Report China 2 Q 2018 The following report presents Dow Jones VentureSource s quarterly findings for Chinese venture capital fundraising, investment, valuation, and liquidity. The included

More information

Trends in Healthcare Investments and Exits 2018

Trends in Healthcare Investments and Exits 2018 Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview

More information

Advisors. Firm Overview

Advisors. Firm Overview Advisors Firm Overview NRS Advisors Private Limited NRS House, B-4 Himmatlal Park, Opp. Azad Muni. Garden, Satellite, Ahmedabad - 380015 Gujarat, India NRS Overview NRS Advisors is a leading provider of

More information

PwC s Academy. Mastering. Mergers & Acquisitions

PwC s Academy. Mastering. Mergers & Acquisitions PwC s Academy Mastering Mergers & Acquisitions Developing and managing a successful portfolio of businesses requires taking the right path to acquire, redeploy or divest resources and capabilities. Whether

More information

Venture Capital Search Highlights

Venture Capital Search Highlights Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more

More information

Energy. Practice. Group

Energy. Practice. Group Energy Practice Group The Energy Practice Group is a multi-disciplinary group of investment banking advisors within Corporate Finance Associates. Collectively, the Energy Practice Group provides M&A advice

More information

Manatt Digital 2016 REPRESENTATIVE TRANSACTIONS AND CLIENTS

Manatt Digital 2016 REPRESENTATIVE TRANSACTIONS AND CLIENTS Manatt Digital 2016 REPRESENTATIVE TRANSACTIONS AND CLIENTS Turning optimism into opportunities. Acorn Technologies Series B Financing AktaryTech Counsel to Lead Investor AthliOS Company Formation and

More information

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Enayat Qasimi. Partner. Experience M Street, NW Suite 450N Washington, DC Phone: Fax:

Enayat Qasimi. Partner. Experience M Street, NW Suite 450N Washington, DC Phone: Fax: 2018 Whiteford, Taylor & Preston LLP Enayat Qasimi Partner 1800 M Street, NW Suite 450N Washington, DC 20036 Phone: 202.659.6792 Fax: 202.327.6174 Email: eqasimi@wtplaw.com Experience Mr. Qasimi?s practice

More information

PE Monthly Roundup July 2017

PE Monthly Roundup July 2017 PE Monthly Roundup y 20 PE/VC headline trends Monthly US$ mn # Investments,000 0 0 9,000 0 9 2 0 2,000 0 0,000 9,00,2, 92,02,9 9 2,,920,,0, 20-0 - Aug- Sep- Oct- Nov- Dec- Jan- Feb- Mar- - - - -,00,000

More information

GLOBAL RISK AND INVESTIGATIONS JAPAN CAPABILITY STATEMENT

GLOBAL RISK AND INVESTIGATIONS JAPAN CAPABILITY STATEMENT GLOBAL RISK AND INVESTIGATIONS JAPAN CAPABILITY STATEMENT CRITICAL THINKING AT THE CRITICAL TIME ABOUT US The Global Risk and Investigations Practice (GRIP) of FTI Consulting is the leading provider of

More information

DOWNLOAD OR READ : VENTURE CAPITAL INVESTMENTS IN THE RENEWABLE ENERGY INDUSTRY PDF EBOOK EPUB MOBI

DOWNLOAD OR READ : VENTURE CAPITAL INVESTMENTS IN THE RENEWABLE ENERGY INDUSTRY PDF EBOOK EPUB MOBI DOWNLOAD OR READ : VENTURE CAPITAL INVESTMENTS IN THE RENEWABLE ENERGY INDUSTRY PDF EBOOK EPUB MOBI Page 1 Page 2 venture capital investments in the renewable energy industry venture capital investments

More information

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back.

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back. Renew-New PHARMA S NEW PHASE Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom They re back. Mergers & acquisitions, that is and in a big way. Wall Street and City

More information

EVCA Strategic Priorities

EVCA Strategic Priorities EVCA Strategic Priorities EVCA Strategic Priorities The following document identifies the strategic priorities for the European Private Equity and Venture Capital Association (EVCA) over the next three

More information

mergers & acquisitions all your transactions are a big deal to us

mergers & acquisitions all your transactions are a big deal to us mergers & acquisitions all your transactions are a big deal to us Did you know? The Takeover Panel is consulting on new powers to enable enforcement of post-offer undertakings in a public takeover offer.

More information

BDO & PITCHBOOK: SHATTERING OF INDUSTRY, GLOBAL SILOS DRIVES HEALTHCARE DEAL ACTIVITY

BDO & PITCHBOOK: SHATTERING OF INDUSTRY, GLOBAL SILOS DRIVES HEALTHCARE DEAL ACTIVITY BDO & PITCHBOOK: SHATTERING OF INDUSTRY, GLOBAL SILOS DRIVES HEALTHCARE DEAL ACTIVITY CONTENTS SECTION Frothy Political Waters Could Dampen Cross-Border Opportunity with China 3 SECTION China as the New

More information

Venture Capital Research Report Q4 2017

Venture Capital Research Report Q4 2017 Venture Capital Research Report Q4 2017 As of February 9, 2018 Executive Summary VC market in the US Regional share of investment VC market in the SF Bay Area Annual VC investment in the SF Bay Area VC

More information

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market

More information

Information Technology: McGladrey Quarterly Private Equity Deal Flow Profile

Information Technology: McGladrey Quarterly Private Equity Deal Flow Profile Information Technology: McGladrey Quarterly Private Equity Deal Flow Profile Q3 2011 Insight Analysis Experience the power of being understood. SM Powered by PitchBook McGladrey Announces the Q3 2011 Private

More information

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS INDUSTRY RE FUNDS 1969 to present Industry surveys, quarterly and annual fund reports 9,240+ venture capital and private equity funds Venture capital and buyout funds that have invested in companies Name

More information

PANEL DISCUSSION & ROUNDTABLES

PANEL DISCUSSION & ROUNDTABLES LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the

More information

Moore Thompson: the corporate finance experts

Moore Thompson: the corporate finance experts Moore Thompson: the corporate finance experts www.moorethompson.co.uk Let s talk about corporate finance... To keep your business running efficiently and effectively, there are times when you will need

More information

Q Q Cleantech Investment Monitor VOL. 7 / ISSUE 1.

Q Q Cleantech Investment Monitor VOL. 7 / ISSUE 1. Q1 2008 Q1 2008 VOL. 7 / ISSUE 1 Cleantech Investment Monitor we put the squeaky in your CLEAN If you are a cleantech leader looking to engage advocates worldwide with strategic PR, please contact: William

More information

As our brand migration will be gradual, you will see traces of our past through documentation, videos, and digital platforms.

As our brand migration will be gradual, you will see traces of our past through documentation, videos, and digital platforms. We are now Refinitiv, formerly the Financial and Risk business of Thomson Reuters. We ve set a bold course for the future both ours and yours and are introducing our new brand to the world. As our brand

More information